On May 28, 2019, PUMCH signed a strategic cooperation agreement with Singapore-based Tessa Therapeutics. Present at the signing ceremony were: PUMCH President Zhao Yupei, NHC Department of Health Science, Technology and Education Director Yang Qing and Division Chief Gu Jinhui, PUMCH Vice President Zhang Shuyang, and Tessa Therapeutics CEO Andrew Khoo.
Tessa Therapeutics is a world leader in VST therapy, which boasts unique advantages in the treatment of nasopharyngeal carcinoma, lymphoma, cervical cancer, breast cancer, gastric cancer, and lung cancer. The therapy, which is under global multi-center clinical trials, will also slash patient costs.
The agreement marks a new starting point in China-Singapore medical cooperation. The two parties will, relying on PUMCH’s clinical advantage and Tessa Therapeutics’ new technology, join hands to provide more individualized, more effective therapies and therefore promote human healthcare.
Leaders of the two sides at the signing ceremony